Bayer adds AAV-based gene therapy tech in $2bn AskBio buy
The deal – which could be worth up to $4 billion – bolsters Bayer's gene therapy ambitions through the addition of an AAV manufacturing platform, clinical-stage candidates, and a CDMO unit. German pharma giant Bayer is paying $2 billion up front with potential milestone payments up to another ...
In a deal worth up to $37.6 million, live biotherapeutic (LBP) developer 4D Pharma has agreed to merge with Longevity Acquisition Corporation.
...
Bioprocess Insider editor Dan Stanton joins an industry panel to discuss supply chain concerns stemming from the ongoing coronavirus crisis. List ...
Danaher Corporation says its bioprocessing businesses Pall Biotech and Cytiva have secured over $1 billion in COVID-19 related orders and expects ...
Sartorius has raised its guidance citing growing demand for bioprocessing tech and lab services and the positive impact of acquisitions.
Group ...
Recent Tweets
-
RT @Dan5tanton: @BayerPharma adds AAV tech, #genetherapy pipeline, and #CDMO unit in $2bn AskBio buy https://t.co/3SxrZdn4yZ https://t.co/bulE2ZUCD3
1 day ago
-
RT @Dan5tanton: A facility in Geneva will be home to two of JSR Life Sciences acquisitions - Selexis and KBI - offering customers b… https://t.co/cIKFtnSLKu
6 days ago
-
Humanigen has partnered with Thermo Fisher for the manufacture of its potential COVID-19 therapy lenzilumab as it e… https://t.co/9YKqfGPy4D
1 month ago
-
RT @Dan5tanton: From flu jabs, to mAbs, to #COVID #mRNA collabs: BioNTech nabs Novartis plant and labs https://t.co/LXvdXTlIBW https://t.co/ARj9kJNThH
1 month ago
Trending
Manufacturing
eBook: Trends in Facility Design —
In-House Manufacturing Considerations for Cell and Gene Therapy ProductionDownstream Processing
eBook: Viral Vector Purification —
A Discussion of Current Challenges and MethodsUpstream Processing
Updating the Economics of Biologics Manufacturing with 5,000-L Single-Use Bioreactors: A Paradigm Shift
BPI White Papers
Do Not Let HCPs Delay Your Biologics Route to Market